🔓
Sign in as a Member to unlock the full view of HRES.1285. · Full carveout list, all affected companies, party defectors, and 30-day trade predictions.
Become a Member$24.50/mo already a Member? Sign in →
HRES.1285 · 119TH CONGRESS

Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.

Status
In Committee
Latest Action
2026-05-14
Sponsor
DeGette, Diana (D-Colorado)
Official Source
Investability
0/100
Stage
COMMITTEE
Related Bills
1
Full Text
Unavailable
Alive
Yes

What This Bill Does · Plain English

Summary
Plain-English summary not yet available for this bill. Check back after our next analysis run.

Frequently Asked Questions

Did HRES.1285 pass?
HRES.1285 is still alive. Current stage: COMMITTEE. Pass likelihood: pending.
Who sponsored HRES.1285?
HRES.1285 was sponsored by Diana DeGette (D-Colorado).

Full Bill Text

Full text not yet indexed for this bill. Check Congress.gov for the official text.
🔒 GovGreed Pro · Trading Intelligence on HRES.1285 Get Access — $24.50/mo
Loading intelligence layer…
Bill text sourced from GovInfo.gov · public domain · last updated 2026-07-29. Plain-English summary, score breakdown, and trading-intelligence panels are GovGreed-original analysis derived from STOCK Act filings, SEC Form 4 disclosures, FEC contributions, and Senate LDA lobbying reports — all publicly filed federal records. GovGreed is not affiliated with the U.S. Government. Not financial advice. [live render]